LO7 : A single subcutaneous dose of 2mg/kg or 4mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against MIR-122, results in significant viral load reductions in chronic hepatitis C patients

GWAS hits were validated in independent cohorts from Germany (529 cases vs. 761 controls) and Belgium (619 cases vs. 161 controls) and the results of the joint analyses combined. Genotyping was undertaken using Illumina BeadChips (Illumina Inc., San Diego, CA, USA); SNP replication was undertaken using Taqman chemistry (Applied Biosystems, Foster City, Ca, USA) on an automated platform. Results: The strongest association signal in the initial metaanalysis was observed between the rs738409 variant in PNPLA3 (Pmeta =1.17×10−28, OR=2.38 [2.08–2.69]); 102 separate variants at the PNPLA3 locus associated with genome-wide significance (Pthreshold <5×10−8). In addition, nine other independent loci provided borderline association signals (Pthreshold ≤1.1×10−5). Validation genotyping for rs738409 in PNPLA3 and lead markers for the top 10 associated regions confirmed disease association for rs738409 in PNPLA3, and for (MBOAT7: rs641738 Preplication = 1.35×10−4; Pcombined = 9.25×10−10; OR=1.63 [1.46–1.80] and TM6SF2: rs10401969 Preplication = 3.29×10−5; Pcombined = 1.73×10−8; OR=1.35 [1.25–1.44]).